Dystrophic epidermolysis bullosa (DEB) is an incurable, inherited mechano-bullous disease of the skin characterized by skin fragility, blister formation, and chronic wounds. DEB is caused by defects in the human gene encoding type VII collagen. Type VII collagen is the main component of anchoring fibrils, structures within the basement membrane of skin which are attenuated, diminutive, or absent in DEB. These structures are thought to anchor the epidermis to the dermis, and their paucity in DEB results in the skin features. Gene therapy is considerated one strategy to correct this defect. The long-term objective of this proposal is to develop an ex vivo gene therapy strategy for DEB. We propose the targeted introduction of a transgene coding for type VII collagen into cultured keratinocytes and fibroblasts from DEB patients, cells that cannot endogenously make this protein. The """"""""gene corrected"""""""" cell cultures would then be transplanted onto the patients as an autograft. We have constructed both of full-length type VII collagen and a truncated type VII minicollagen plasmid expression vectors and purified large quantities of the recombinant proteins from stably transfected human cells. The minicollagen although truncated retains all the functional properties of a full-length alpha chain. Using a retroviral-mediated expression vector, we have induced RDEB keratinocytes to express the minicollagen which reversed the RDEB cellular phenotype to that of normal keratincytes. In this proposal, we will build upon this work and develop highly efficient viral vectors that will allow sustained and targeted type VII collagen transgene delivery into human keratinocytes and fibroblasts. We will generate new minigene and full length type VII collagen delivery vehicles using lentiviral vectors which can offer high efficiency, sustained transgene expression and the ability to transduce nondividing cells and can accommodate the 9 kb full-length type VII collagen Cdna. We will also use vectors with cellular promoters, such as the K14 promoter, to promote sustained expression and target the basal keratinocytes. Using our well- established assays, we will examine the phenotype and cellular functions of """"""""gene-corrected"""""""" RDEB cells. Lastly, we will advance from our monolayer keratinocyte and fibroblast cultures to a three dimensional, composite, skin- equivalent, organotypic culture model with diseased and """"""""gene corrected"""""""" RDEB cells. These cultures will also be grafted onto SCID mice and evaluated for anchoring fibril formation and sustained expression of the transgenes for type VII collagen.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
1R01AR047981-01
Application #
6368898
Study Section
Special Emphasis Panel (ZRG1-SSS-M (02))
Program Officer
Moshell, Alan N
Project Start
2001-08-01
Project End
2005-05-31
Budget Start
2001-08-01
Budget End
2002-05-31
Support Year
1
Fiscal Year
2001
Total Cost
$284,375
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Hill, David S; Robinson, Neil D P; Caley, Matthew P et al. (2015) A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion. Mol Cancer Ther 14:2665-73
Woodley, David T; Cogan, Jon; Wang, Xinyi et al. (2014) De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 134:1138-1140
Cogan, Jon; Weinstein, Jacqueline; Wang, Xinyi et al. (2014) Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Mol Ther 22:1741-52
Woodley, David T; Wang, Xinyi; Amir, Mahsa et al. (2013) Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J Invest Dermatol 133:1910-3
Wang, Xinyi; Ghasri, Pedram; Amir, Mahsa et al. (2013) Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure. Mol Ther 21:1335-44
Gupta, Rishu; Woodley, David T; Chen, Mei (2012) Epidermolysis bullosa acquisita. Clin Dermatol 30:60-9
Chen, Mei; Kim, Gene H; Prakash, Lori et al. (2012) Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. Autoimmunity 45:91-101
Remington, Jennifer; Wang, Xinyi; Hou, Yingpin et al. (2009) Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17:26-33
Woodley, David T; Hou, Yingping; Martin, Sabrina et al. (2008) Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis. J Biol Chem 283:17838-45
Woodley, David T; Remington, Jennifer; Huang, Yi et al. (2007) Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 15:628-35

Showing the most recent 10 out of 19 publications